Ngā hua rapu - V. Diéras

  • E whakaatu ana i te 1 - 5 hua o te 5
Whakamahine hua
  1. 1
    Does a Geriatric Oncology Consultation Modify the Cancer Treatment Plan for Elderly Patients?

    Does a Geriatric Oncology Consultation Modify the Cancer Treatment Plan for Elderly Patients? mā V. Girre, Marie-Christine Falcou, Mathilde Gisselbrecht, G. Gridel, V. Mosseri, Carole Bouleuc, Rollon Poinsot, Lionel Védrine, Luc Ollivier, Valérie Garabige, J. Y. Pierga, V. Diéras, L. Mignot

    I whakaputaina 2008
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130

    Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130 mā H. S. Rugo, Sherene Loi, Sylvia Adams, Peter Schmid, Andreas Schneeweiß, C.H. Barrios, Hiroji Iwata, V. Diéras, EP Winer, Mark Kockx, Dieter Peeters, Jane Yuet Ching Hui, J. Lin, Anh Nguyen Duc, Giulia Viale, Luciana Molinero, Leisha A. Emens

    I whakaputaina 2019
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours

    REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours mā Christelle Lévy, Djelila Allouache, Joëlle Lacroix, A. Dugué, S. Supiot, Mario Campone, Marc-André Mahé, Salim Kichou, Marianne Leheurteur, C. Hanzen, V. Diéras, Youlia Kirova, F. Campana, Émilie Le Rhun, L. Gras, T Bachelot, Marie Pierre Sunyach, I. Hrab, Julien Geffrelot, K. Gunzer, Jean‐Marc Constans, Jean‐Michel Grellard, Bénédicte Clarisse, Xavier Paolettí

    I whakaputaina 2014
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Sacituzumab govitecan in metastatic triple-negative breast cancer

    Sacituzumab govitecan in metastatic triple-negative breast cancer mā A. Bardia, S.A. Hurvitz, S.M. Tolaney, D. Loirat, K. Punie, M. Oliveira, A. Brufsky, S.D. Sardesai, K. Kalinsky, A.B. Zelnak, R. Weaver, T. Traina, F. Dalenc, P. Aftimos, F. Lynce, S. Diab, J. Cortés, J. O apos Shaughnessy, V. Diéras, C. Ferrario, P. Schmid, L.A. Carey, L. Gianni, M.J. Piccart, S. Loibl, D.M. Goldenberg, Q. Hong, M.S. Olivo, L.M. Itri, H.S. Rugo, ASCENT Clinical Trial Investigators

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

    ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer mā P. Tarantino, Giulia Viale, Michael F. Press, Xin Hu, Frédérique Penault‐Llorca, A. Bardia, Anna Batistatou, H.J. Burstein, L.A. Carey, Javier Cortés, C. Denkert, V. Diéras, William Jacot, A. Koutras, Alizée Lebeau, S. Loibl, Shanu Modi, M.F. Mosele, Elena Provenzano, Giancarlo Pruneri, Jorge S. Reis‐Filho, Federico Rojo, Roberto Salgado, P. Schmid, Stuart J. Schnitt, S.M. Tolaney, Dario Trapani, A. Vincent-Salomon, A.C. Wolff, George Pentheroudakis, Fabrice André, G. Curigliano

    I whakaputaina 2023
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: